URL details: lioncitylife.com/jcn-newswire/eisai-to-divest-rights-for-anti-epileptic-drug-fycompa-perampanel-ciii-in-united-states-to-catalyst-pharmaceuticals/

home > domains > lioncitylife.com > lioncitylife.com/jcn-newswire/eisai-to-divest-rights-for-anti-epileptic-drug-fycompa-perampanel-ciii-in-united-states-to-catalyst-pharmaceuticals/

URL title: Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals – Lion Cit
URL paragraphs: TOKYO, Dec 20, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa (generic name: perampanel) C
URL last crawled: 2022-12-20
URL speed: 0.338 MB/s, downloaded in 0.090 seconds

open external url

We found no external links pointing to this url.